Related Experiment Video
Updated: Mar 8, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Caleb Dulaney1, Samuel Marcrom1, Jennifer Stanley1
1Department of Radiation Oncology, University of Alabama at Birmingham, 1700 6th Avenue South, 176F Hazelrig-Salter Radiation Oncology Center, Room 2232-N, Birmingham, AL 35249-6832, United States.
Abstract:
Genomic instability resultant from defective DNA repair mechanisms is a fundamental hallmark of cancer. The poly(ADP-ribose) polymerase (PARP) proteins 1, 2 and 3 catalyze the polymerization of poly(ADP-ribose) and covalent attachment to proteins in a phylogenetically ancient form of protein modification. PARPs play a role in base excision repair, homologous recombination, and non-homologous end joining. The discovery that loss of PARP activity had cytotoxic effects in cells deficient in homologous recombination has sparked a decade of translational research efforts that culminated in the FDA approval of an oral PARP inhibitor for clinical use in patients with ovarian cancer and defective homologous recombination. Five PARP inhibitors are now in late-stage development in clinical trials that are seeking to expand the understanding of targeted therapies and DNA repair defects in human cancer. This review examines the cell biology of PARP, the discovery of synthetic lethality with HR deficiency, the clinical development of PARP inhibitors, and the role of PARP inhibitors in ongoing clinical trials and clinical practice.
Insights
Poly(ADP-ribose) polymerase (PARP) inhibitors exploit cancer
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genomic instability, driven by faulty DNA repair, is a key cancer characteristic.
- Poly(ADP-ribose) polymerase (PARP) proteins are crucial for DNA repair pathways like homologous recombination (HR).
Purpose of the Study:
- To review the cell biology of PARP proteins.
- To discuss the discovery of synthetic lethality in homologous recombination-deficient cancers.
- To examine the clinical development and application of PARP inhibitors.
Main Methods:
- Literature review of PARP biology, DNA repair mechanisms, and clinical trial data.
- Analysis of synthetic lethality principles in cancer therapy.
- Examination of FDA-approved PARP inhibitors and ongoing clinical trials.
Main Results:
- PARP inhibitors demonstrate efficacy in cancers with defective homologous recombination.
- Five PARP inhibitors are in late-stage clinical development.
- PARP inhibitors represent a significant advancement in targeted cancer therapy.
Conclusions:
- PARP inhibitors are effective targeted therapies for specific cancer types.
- Ongoing research aims to broaden the application of PARP inhibitors.
- Understanding DNA repair defects is crucial for advancing cancer treatment.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
Biosynthesis of Nucleic Acids
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

